Is good old minocycline a new neuroprotective drug?;¿Es la vieja minociclina un nuevo fármaco neuroprotector?

Revista de Neurologia

Volumn 47, Issue 1, 2008, Pages 31-38

  Melero Fernandez De Mera R M ^a,e   Garcia Martinez E ^b   Fernandez Gomez F J ^a,e   Hernandez Guijo J M ^c   Aguirre, N ^d   Galindo, M F ^b   Jordán, Joaquín ^a,e,f  

^a Universidad de Castilla La Mancha   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c INSTITUTO TEÓFILO HERNANDO   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

^e University of Castilla La Mancha   (Spain)

^f UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Apoptosis; Inflammation; Microglial cell; Minocycline; Mitochondria; Neurodegeneration; Neuroprotection; Oxidative stress; Tetracyclines

Indexed keywords

CELECOXIB; CREATINE; DOXYCYCLINE; INTERLEUKIN 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PLACEBO; RILUZOLE; TUMOR NECROSIS FACTOR; NEUROPROTECTIVE AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; ANEURYSM; ANTIOXIDANT ACTIVITY; APOPTOSIS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR MALFORMATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; PARKINSON DISEASE; RATING SCALE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL;

ANIMALS; APOPTOSIS; HUMANS; MINOCYCLINE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 46749121735     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4701.2008065     Document Type: Review

References (96)

1. European Medicines Agency (EMEA). URL: www.emea.europa.eu. [22.02.2008].
2. U.S. Food and Drug Administration. URL: www.fda.gov/oc/spanish. [03.04.2008].
3. Martindale. Guía completa de consulta farmacoterapéutica 2006. 2 ed. URL: www.emartindale.com. [25.03.2008].
4. Thomson Healthcare. URL: www.micromedex.com. [12.02.2008].
5. Crosby N, Deane KH , Clarke CE. Amantadine in Parkinson's disease. Cochrane Database Syst Rev 2003; (1): CD003468.
6. Macdonald H, Nelly RG, Allen ES, Noble JF, Canjeéis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973; 14: 852-61.
7. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998; 95: 15769-74.
8. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 1999; 96: 13496-500.
9. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001; 166: 7527-33.
10. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001; 21: 2580-8.
11. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004; 24: 2182-90.
12. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 2001; 98: 14669-74.
13. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001; 909: 187-93.
14. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22: 1763-71.
15. Fernández-Gómez FJ, Gómez-Lázaro M, Pastor D, Calvo S, Aguirre N, Galindo MF, et al. Minocycline fails to protect cerebellar granular cell cultures against malonate-induced cell death. Neurobiol Dis 2005; 20: 384-91.
16. Fernández-Gómez FJ, Galindo MF, Gómez-Lázaro M, González-García C, Ceña V, Aguirre N, et al. Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. Neuroscience 2005; 133: 959-67.
17. Goni-Allo B, Ramos M, Jordán J, Aguirre N. In vivo studies on the protective role of minocycline against excitotoxicity caused by malonate or N-methyl-D-aspartate. Exp Neurol 2005; 191: 326-30.
18. Tsuji M, Wilson MA, Lange MS, Johnston MV. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp Neurol 2004; 189: 58-65.
19. Jordán J, Fernández-Gómez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF. Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 2007; 4: 225-31.
20. Diguet E, Gross CE, Tison F, Bezard E. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Exp Neurol 2004; 189: 1-4.
21. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, et al. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 2003; 74: 278-85.
22. Chambers HF. Antimicrobial agents: protein synthesis inhibitors and miscellaneous antibacterial agents. In Hardman JG, Limbird AG, eds. The pharmacological basis of therapeutics. 10 ed. New York: McGraw-Hill Professional 2001. p. 1240-6.
23. Arango-Lasprilla JC, Iglesias-Dorado J, Lopera F. Características clínicas y neuropsicológicas de la enfermedad de Huntington: una revisión. Rev Neurol 2003; 37: 758-65.
24. De Toledo M. Inflamación y enfermedad de Alzheimer. Rev Neurol 2006; 42: 433-8.
25. Ferrer I. Mecanismos de muerte neuronal en la isquemia cerebral. Rev Neurol 1999; 29: 515-21.
26. Jiménez del Río M, Vélez-Pardo C. Apoptosis en enfermedades neurodegenerativas: hechos y controversias. Rev Neurol 2001; 32: 851-60.
27. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-27.
28. Tomas-Camardiel M, Rite I, Herrera AJ, De Pablos RM, Cano J, Machado A, et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 2004; 16: 190-201.
29. Suk K. Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci Lett 2004; 366: 167-71
30. Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 2004; 27: 314-8.
31. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-308.
32. Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006; 53: 776-82.
33. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-8.
34. Vagnucci AH Jr, Li WW. Alzheimer's disease and angiogenesis. Lancet 2003; 361: 605-8.
35. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev 2005; 57: 173-85.
36. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64: 575-611.
37. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991; 51: 672-5.
38. Ryu JK, McLarnon JG. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol 2006; 198: 552-7.
39. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LLJ, Del Zoppo GJ. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004; 35: 998-1004.
40. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996; 16: 360-6.
41. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, Del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-3.
42. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, et al. Doseresponse effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab 2006; 26: 1157-64.
43. Paemen L, Martens E, Norga K, Masure S, Roets E, Hoogmartens J, et al. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 1996; 52: 105-11.
44. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, et al. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab 2005; 25: 460-7.
45. 2+ signalling in hippocampal neurons. Eur J Neurosci 2007; 26: 2481-95.
46. Estévez AG, Jordán J. Nitric oxide and superoxide, a deadly cocktail. Ann N Y Acad Sci 2002; 962: 207-11.
47. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 2005; 94: 819-27.
48. Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, Jin BK. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 2005; 95: 1755-65.
49. Chao PY, Allen KG. Glutathione production in copper-deficient isolated rat hepatocytes. Free Radic Biol Med 1992; 12: 145-50.
50. Chabot S, Yong FP, Le DM, Metz LM, Myles T, Yong VW. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler 2002; 8: 299-306.
51. Fernández-Gómez FJ, Galindo MF, Gómez-Lázaro M, Yuste VJ, Comella JX, Aguirre N, et al. Malonate induces cell death via mitochondrial potential collapse and delayed swelling through an ROS-dependent pathway. Br J Pharmacol 2005; 144: 528-37.
52. Jordán J, Galindo MF, Tornero D, Benavides A, González C, Agapito MT, et al. Superoxide anions mediate veratridine-induced cytochrome C release and caspase activity in bovine chromaffin cells. Br J Pharmacol 2002; 137: 993-1000.
53. Pi R, Li W, Lee NT, Chan HH, Pu Y, Chan LN, et al. Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J Neurochem 2004; 91: 1219-30.
54. Fernández-Gómez FJ, Pastor MD, García- Martínez EM, Melero-Fernández de Mera R, Gou-Fábregas M, Gómez-Lázaro M, et al. Pyruvate protects cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the Akt signaling pathway and increasing glutathione peroxidase expression. Neurobiol Dis 2006; 24: 296-307.
55. Kennedy SG, Wagner AJ, Conzen SD, Jordán J. Bellacosa A, Tsichlis PN, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11: 701-13.
56. Lin S, Wei X, Bales KR, Paul AB, Ma Z, Yan G, et al. Minocycline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia-induced cerebellar hypoplasia in the Gunn rat. Eur J Neurosci 2005; 22: 21-7.
57. Wei X, Zhao L, Liu J, Dodel RC, Farlow MR, Du Y. Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation. Neuroscience 2005; 131: 513-21.
58. Nikodemova M, Duncan ID, Watters JJ. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem 2006; 96: 314-23.
59. Jordán J, Ceña V, Prehn JH. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J Physiol Biochem 2003; 59: 129-41.
60. Tornero D, Ceña V, González-García C, Jordán J. Papel del poro de permeabilidad transitoria mitocondrial en los procesos neurodegenerativos. Rev Neurol 2002; 35: 354-61.
61. Ravagnan L, Roumier T, Kroemer G. Mitochondria, the killer organelles and their weapons. J Cell Physiol 2002; 192: 131-7.
62. Galindo MF, Jordán J, González-García C, Ceña V. Reactive oxygen species induce swelling and cytochrome c release but not transmembrane depolarization in isolated rat brain mitochondria. Br J Pharmacol 2003; 139: 797-804.
63. Gómez-Lázaro M, Galindo MF, Melero-Fernández de Mera RM, Fernández-Gómez FJ, Concannon CG, Segura MF, et al. Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol 2007; 71: 736-43.
64. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 2004; 279: 19948-54.
65. Jordán J, Galindo MF, Ceña V, González-García C. Cisteina proteasas y neurodegeneración. Rev Neurol 2000; 31: 333-40.
66. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797-801.
67. Scarabelli TM, Stephanou A, Pasini E, Gitti G, Townsend P, Lawrence K, et al. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 2004; 43: 865-74.
68. Bonelli RM, Hödl AK, Hofmann P, Kapfhammer HP. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 2004; 19: 337-42.
69. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord 2004; 19: 692-5.
70. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 2004; 63: 547-9.
71. Reynolds N. Revisiting safety of minocycline as neuroprotection in Huntington's disease. Mov Disord 2007; 22: 292.
72. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al, for the Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-53.
73. Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol Sci 2005; 26: 285-7.
74. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664-71.
75. German Parkinson Study Group (GPS). Study about efficacy and safety to treat multi-system-atrophy. URL: www.clinicaltrials.gov. Identifier: NCT00146809. [25.03.2008].
76. Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007; 13: 517-26.
77. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404-10.
78. Wang KK, Larner SF, Robinson G, Hayes RL. Neuroprotection targets after traumatic brain injury. Curr Opin Neurol 2006; 19: 514-9.
79. Fu ES, Tummala RP. Neuroprotection in brain and spinal cord trauma. Curr Opin Anaesthesiol 2005; 18: 181-7.
80. Baptiste DC, Fehlings MG. Update on the treatment of spinal cord injury. Prog Brain Res 2007; 161: 217-33.
81. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996; 93: 14014-9.
82. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-78.
83. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PAS, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003; 54: 186-196.
84. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, et al. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 2003; 74: 278-85.
85. Diguet E, Rouland R, Tison F. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease. Ann Neurol 2003; 54: 841-2.
86. Diguet E, Gross CE, Bezard E, Tison F, Stefanova N, Wenning GK. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2004; 62: 158 [author reply 158-9].
87. Corbett D, Nurse S. The problem of assessing effective neuroprotection in experimental cerebral ischemia. Prog Neurobiol 1998; 54: 531-48.
88. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004; 25: 62: 1845-7.
89. Bedlack R. A multicenter, phase III randomized double-blind, placebo-controlled clinical trial of minocycline in 400 subjects with ALS. NINDS, Columbia 2003-2007; NIH RO1 NS045294-01.
90. Gordon PH. Combination therapy selection trial in amyotrophic lateral sclerosis. Columbia University 2006. URL: www.clinicaltrials.gov. Identifier: NCT00355576. [01.04.2008].
91. Cheung YK, Gordon PH, Levin B. Selecting promising ALS therapies in clinical trials. Neurology 2006; 67: 1748-51.
92. Denovan-Wright EM, Devarajan S, Dursun SM, Robertson HA. Maintained improvement with minocycline of a patient with advanced Huntington's disease. J Psychopharmacol 2002; 16: 393-4.
93. Cudkowicz M, Friedlander R, Marshall F. MINO: Minocycline dosing and safety in Huntington's disease (HD). Pilot study of minocycline. Products Division Huntington Study Group. FDA Office of Orphan Products Development. URL: www.huntington-study-group.org/MINOAbstract.htm [14.02.2008].
94. Preliminary study shows creatine and minocycline may warrant further study in Parkinson's disease 2006. In: National Institute of Neurological Disorders and Stroke (NINDS). URL: www.nih.gov/news/pr/feb2006/ninds-23.htm. [30.01.2008].
95. Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007; 13: 517-26.
96. University of California, San Francisco. Tetracycline-derivatives for treatment of cerebral arteriovenous malformations and aneurysm. URL: www.clinicaltrials.gov. Identifier: NCT00305994. [16.05.2008].